Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
thanks Las3r for your great and detailed explanation ... I am only catching up again.... best of good fortune to all...
I also want to thank all the folks that posted here, and I hope to see you in TLRY.
Congratulations to all!
My shares in TDA did, but not my shares in F. I am sure they will in a day or two....
Same here, see you in the other side
Farewell friends. See you all on the Tilray board. Maybe you can sign my yearbook before you go?
My APHA shares just changed to Tilray. That was quick.
Today APHA & TLRY announced that the merger is officially closed. Yay! Ok, but what does this mean for my stock??
If you were a holder of APHA shares as of 4/30/21 (Friday), each of your APHA shares will turn into 0.8381 shares of TLRY. This means that if you had 100 APHA shares, you will now have 83.81 shares of TLRY. Keep in mind there are NO fractional shares. This means that if your shares come out to 83.81, you will only receive 83 shares of TLRY. That number is always rounded DOWN, not up and there will be NO CASH to compensate you for your fractional share (so you can lose at most 0.99 shares of TLRY depending on how much APHA you have - which is like ~$18.56 (if TLRY is at $18.75))
If you were a holder of TLRY shares you are STILL a holder of TLRY shares. Nothing changes for you. In the announcement, the company mentions the TSX listing, but this is a DUAL LISTING. TLRY will continue to trade on NASDAQ. TLRY will ALSO trade under the symbol "TLRY" on the Toronto Stock Exchange (TSX) starting May 5th. Really nothing for you to do here, just gives you the ability to trade them on either exchange - it provides extra liquidity.
Another thing to keep in mind is the "back office" - this happens at big banks and at big hedge funds too. APHA has HALTED today and will no longer trade. TECHNICALLY you now own TLRY shares that were given to you in the merger. When those show up in your account and you have the ability to freely trade those depends on what broker you use. If you're worried about it - call them. If you want to buy TLRY today, you can. Just go buy more and then the APHA shares that converted to TLRY will be added to your position when everything settles with your broker.
Tilray & Aphria Announce Closing of Transaction That Creates the “New” Tilray – a Global Cannabis Leader
May 3, 2021 at 6:00 AM EDT
https://ir.tilray.com/news-releases/news-release-details/tilray-aphria-announce-closing-transaction-creates-new-tilray
Operational Efficiencies Expected to Generate Approximately US$81 Million Annual Pre-Tax Cost-Saving Synergies for New Tilray Within Eighteen Months
Irwin D. Simon, Aphria’s Chairman and CEO, will Lead the New Tilray and Has Appointed New Executive Leadership Team; New Members of the Board of Directors Also Appointed
New Tilray Poised to Transform the Global Cannabis Industry as a Consumer Packaged Goods Powerhouse with a Diversified Portfolio of Leading Brands
Renewed Financial Strength to Drive Accelerated Growth Strategy and Sustained Profitability
Tilray’s Shares Will Continue Trading on the NASDAQ Under Symbol “TLRY”; Starting May 5, 2021, Tilray’s Shares Will Commence Trading on the Toronto Stock Exchange Under Symbol “TLRY”
NEW YORK & LEAMINGTON, Ontario--(BUSINESS WIRE)--May 3, 2021-- Tilray, Inc. (“Tilray”) and Aphria Inc. (“Aphria”) today announced the completion of the previously announced business combination, ushering in a new era in the global cannabis industry. The combined company, which will operate as Tilray (the “Company”), brings together two highly complementary businesses to create the leading cannabis-focused consumer packaged goods (“CPG”) company with the largest global geographic footprint in the industry. The combined company had a market cap of approximately US$8.2 billion based on the closing stock prices on April 30, 2021.
The Company’s class 2 common stock (“Tilray Shares”) will continue to trade on the Nasdaq Global Select Exchange under the ticker symbol “TLRY” and will commence trading on the Toronto Stock Exchange under the ticker symbol “TLRY” on May 5, 2021. As previously announced, each Aphria shareholder received 0.8381 of a Tilray Share for each Aphria common share (each an “Aphria Share”) held on April 30, 2021, the effective time of the transaction. Holders of Tilray Shares prior to the completion of the transaction continue to hold their Tilray Shares with no adjustment as a result of the transaction. An early warning report in respect of the Company’s acquisition of all of the outstanding Aphria Shares pursuant to the transaction will be filed on SEDAR and will be ?available under Aphria’s issuer profile at www.sedar.com.?
Irwin D. Simon, the Company’s Chairman and Chief Executive Officer, commented, “Our focus now turns to execution on our highest return priorities including business integration and accelerating our global growth strategy. Covid-19 related lockdowns have presented unique challenges across Canadian and German markets. As these markets begin to re-open, Tilray is poised to strike and transform the industry with our highly scalable operational footprint, a curated portfolio of diverse medical and adult-use cannabis brands and products, a multi-continent distribution network, and a robust capital structure to fund our global expansion strategy and deliver sustained profitability and long-term value for our stakeholders.”
Mr. Simon continued, “Our global team is laser-focused on turning potential into performance and addressing consumer and patient needs for safe, innovative, and high-quality products. We are eager to get to work and want to thank both the Aphria and the Tilray Boards of Directors and especially Brendan Kennedy for his spirit of partnership and irrepressible belief in the art of ‘what’s possible.’ We will benefit enormously from his legacy and continued service on the Tilray Board.”
We expect that the business combination will provide, among others, the following financial and strategic benefits:
World’s Largest Global Cannabis Company. The combination of Aphria and Tilray brings together two highly complementary businesses to create the leading cannabis-focused CPG company with the largest global geographic footprint in the industry.
Strategic Footprint and Operational Scale. We believe that the Company has the strategic footprint and operational scale necessary to compete more effectively in today’s consolidating cannabis market with a strong, flexible balance sheet, strong cash balance, and access to capital, which we believe will give the Company the ability to accelerate growth and deliver long-term sustainable value for stockholders.
Low-cost, State-of-the-Art Production & the Leading Canadian Adult-Use Cannabis Producer. The demand for the Company’s products will be supported by low-cost state-of-the-art cultivation, processing, and manufacturing facilities, and it will have a complete portfolio of branded cannabis 2.0 products to strengthen its leadership position in Canada.
Positioned to Pursue an Accelerated International Growth Strategy. The Company is well-positioned to pursue international growth opportunities with its strong medical cannabis brands, distribution network in Germany, and end-to-end European Union Good Manufacturing Practices (“EU-GMP”) supply chain, which includes its production facilities in Portugal and Germany.
Enhanced Consumer Packaged Goods Presence and Infrastructure in the U.S. In the United States, Tilray has a strong consumer packaged goods presence and infrastructure with two strategic pillars, including SweetWater, a leading cannabis lifestyle branded craft brewer, and Manitoba Harvest, a pioneer in branded hemp, CBD and wellness products with access to 17,000 stores in North America. In the event of federal permissibility, the Company expects to be well-positioned to compete in the U.S. cannabis market given its existing strong brands and distribution system in addition to its track record of growth in consumer-packaged goods and cannabis products.
Substantial Synergies. The Company expects to deliver approximately US$81 million (C$100 million) of annual pre-tax cost synergies within eighteen months and plans to achieve cost synergies in the key areas of cultivation and production, cannabis and product purchasing, sales, and marketing, and corporate expenses.
Tilray’s new leadership team and board of directors will provide a strong foundation for the Company to accelerate growth and capitalize on the business combination’s many benefits.
Effective on closing, the senior management team and Board of Directors of the Company were reconstituted as follows:
Irwin D. Simon, Chairman and Chief Executive Officer
Carl Merton, Chief Financial Officer
Denise Faltischek, Head of International and Chief Strategy Officer
Jim Meiers, President, Canada
Jared Simon, President, Manitoba Harvest and Tilray Wellness
Rita Seguin, Chief Human Resources Officer
Dara Redler, Interim Chief Legal Officer and Corporate Secretary
Berrin Noorata, Chief Corporate Affairs Officer
Lloyd Brathwaite, Chief Information Officer
Freddy Bensch, Chief Executive Officer, SweetWater
Board of Directors:
Irwin D. Simon, Chairman
Renah Persofsky, ICD.D, Vice-Chair (Lead Director) and Chair of the Nominating and Governance Committee, Independent Director
Jodi Butts, Nominating & Governance Committee Member, Independent Director
David Clanachan, Newly Appointed Independent Director
John M. Herhalt Chair of the Audit Committee, Independent Director
David Hopkinson, Nominating and Governance Committee & Compensation Committee Member, Independent Director
Brendan Kennedy, Current Director and Former CEO, Tilray
Tom Looney, Audit Committee & Compensation Committee Member, Independent Director
Walter Robb, Chair of the Compensation Committee & Audit Committee Member, Independent Director
New Tilray Branding
The new Tilray logo blends both Aphria and legacy Tilray’s branding into a design that reflects the new Company’s growing portfolio of brands across cannabis-lifestyle and wellness product categories, including medical, adult-use, hemp foods, and beverages. The continued use of “Tilray” as the Company’s name evokes hard work and hope – til shortened from tilling the soil and ray as in a ray of sunshine. Tilray is a pioneer navigating toward the end of prohibition and built to deliver on the collective wellbeing of the Company’s employees, consumers, patients, partners, and local communities.
Advisors
Jefferies LLC served as financial advisor, and DLA Piper LLP (US), DLA Piper (Canada) LLP, and Fasken Martineau Dumoulin LLP acted as legal counsel to Aphria. Cowen served as financial advisor, and Cooley LLP and Blake, Cassels, and Graydon LLP acted as legal counsel to Tilray.
About Tilray
Tilray Inc. is a leading global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is changing people's lives for the better – one person at a time – by inspiring and empowering the worldwide community to live their very best life by providing them with products that meet the needs of their mind, body, and soul and invoke a sense of wellbeing. Tilray’s mission is to be the trusted partner for its patients and consumers by providing them with a cultivated experience and health and wellbeing through high-quality, differentiated brands and innovative products. A pioneer in cannabis research, cultivation, and distribution, Tilray’s unprecedented production platform supports over 20 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and alcoholic beverages.
For more information on how we open a world of wellbeing, visit Tilray.com.
Forward-Looking Statements
Certain information in this communication constitutes forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor created by such sections and other applicable laws. Forward-looking statements are provided for the purpose of presenting information about management’s current expectations and plans relating to the future, and readers are cautioned that such statements may not be appropriate for other purposes. Any information or statements that are contained in this communication that are not statements of historical fact may be deemed to be forward- looking statements, including, but not limited to, statements regarding the expected strategic and financial benefits of the business combination. Words such as “forecast”, “future”, “should”, “could”, “enable”, “potential”, contemplate”, “believe”, “anticipate”, “estimate”, “plan”, “expect”, “intend”, “may”, “project”, “will”, “would” and the negative of these terms or similar expressions identify forward-looking statements, although not all forward-looking statements contain these identifying words. Certain material factors or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements reflect current beliefs of management of the Company with respect to future events and are based on information currently available to each respective management team including the reasonable assumptions, estimates, analysis and opinions of management of the Company considering their experience, perception of trends, current conditions and expected developments as well as other factors that each respective management believes to be relevant as at the date such statements are made. Forward-looking statements involve significant known and unknown risks and uncertainties. Many factors could cause actual results, performance or achievement to be materially different from any future forward-looking statements. There is a risk that some or all the expected benefits of the business combination may fail to materialize or may not occur within the time periods anticipated by the Company. The challenge of coordinating previously independent businesses makes evaluating the business and future financial prospects of the Company following the business combination difficult. Material risks and uncertainties that could cause actual results to differ from forward-looking statements include the inherent uncertainty associated with the financial and other projections a well as market changes arising from governmental actions or market conditions in response to the COVID-19 public health crisis; the prompt and effective integration of the Company; the ability to achieve the anticipated synergies and value-creation contemplated by the business combination; the response of business partners and retention as a result of the business combination; the impact of competitive responses to the business combination; and the diversion of management time on business combination-related issues. Readers are cautioned that the foregoing list of factors is not exhaustive. Other risks and uncertainties not presently known to the Company or that the Company presently believe are not material could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of risks and other factors, see the most recently filed annual information form of Aphria and the annual report filed on form 10-K of Tilray made with applicable securities regulatory authorities and available on SEDAR and EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.
For more information, visit: www.Tilray.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210503005294/en/
Media:
Berrin Noorata
news@tilray.com
Investors
Raphael Gross
203-682-8253
Raphael.Gross@icrinc.com
Source: Tilray, Inc.
Tilray now belongs to us my friend. We have conquered them like in the days of yore when the barbarians raped and pillaged the Roman towns they invaded. All that was Tilray is now ours. Their strong will be put to work in the copper mines, while their weak are vanquished into extinction.
Prepare yourselves Curaleaf, for you are next.
GoSing, kind of. Apria is going to acquire Tilray, but they will keep the symbol TLRY. Apria will control about 62% of the shares. Aphria will become a wholly-owned subsidiary of Tilray. The symbol 'APHA' will be delisted.
https://www.marketwatch.com/story/tilray-stock-rockets-after-reverse-merger-deal-with-aphria-to-create-largest-global-cannabis-company-11608128018
No. They are now part of us.
Tilray already has a symbol and we are now part of it.
I'll believe the world domination part when I see it. I agree with the dump and grace periods.
So, when will my APHA share show ups as TLRY shares?
what is the new symbol?
I expect a dump off, grace period and then the beginning of world domination $$TLRY$$
APHA, first name on the list:...
https://listingcenter.nasdaq.com/IssuersPendingSuspensionDelisting.aspx
Let's see how The Street treats the "new" PPS. Not looking happy today. Maybe Monday after some fanfair we'll know.
Loose some shares, gain some price. Should be interesting.
Aphria to be delisted today after Tilray deal is completed
Apr. 30, 2021 12:06 PM ET
https://seekingalpha.com/news/3688755-aphria-to-be-delisted-today-after-tilray-deal-completed
Aphria Inc. (APHA)By: Josh Fineman, SA News Editor
Aphria's (NASDAQ:APHA) last trading day is today after it complete its deal with Tilray (NASDAQ:TLRY).
The effective date for suspension of the shares is Monday, according to a Nasdaq delisting notice.
Tilray holders were scheduled to vote on the deal at 11am. Earlier this month, Aphria holders approved the proposed merger.
See SA author Cornerstone Investment's piece from earlier this week entitled "Tilray: Mania Ended But Still Frothy."
Tilray-Aphria deal approved in cannabis mega-merger
Fri, April 30, 2021, 12:52 PM
The Tilray and Aphria deal has been approved. Yahoo Finance Canada Senior Writer Jeff Lagerquist joins Yahoo Finance Live to discuss.
https://finance.yahoo.com/video/tilray-aphria-deal-approved-cannabis-165230576.html
Based on this the merger has been approved
https://finance.yahoo.com/video/tilray-aphria-deal-approved-cannabis-165230576.html
I think the bus Tilray sent out to pick up straggling voters had a breakdown and they’re short 7 votes. They are now going door to door using mopeds.
Keep your fingers crossed!
burning is illegal in my state ..............I"d prefer smoking it but not my choice.
How long does it take to count the votes by computer?
I prefer in the 90s. Helps my Italians disease, fundsalow.
Merger news by lunchtime? --->>> Special Meeting of Tilray, Inc. Stockholders Adjourned to April 30, 2021 at 11:00 a.m. Eastern Time
April 15, 2021 07:00 AM Eastern Daylight Time
https://www.businesswire.com/news/home/20210415005291/en/Special-Meeting-of-Tilray-Inc.-Stockholders-Adjourned-to-April-30-2021-at-1100-a.m.-Eastern-Time#:~:text=(NASDAQ%3A%20TLRY)%2C%20a,30%2C%202021%20at%2011%3A00
NANAIMO, British Columbia--(BUSINESS WIRE)--Tilray, Inc. (NASDAQ: TLRY), a global pioneer in cannabis research, cultivation, production, and distribution, today announced that the special meeting of Tilray stockholders (the “Tilray Special Meeting”) scheduled for Friday, April 16, 2021 via live webcast will be convened and then adjourned until Friday, April 30, 2021 at 11:00 a.m. Eastern time via live webcast at www.virtualshareholdermeeting.com/TLRY2021SM, allowing Tilray stockholders additional time to vote on the business combination between Aphria Inc. and Tilray (the “Transaction”).
Tilray stockholders who have already voted do not need to recast their votes. Proxies previously submitted will be voted at the reconvened meeting unless properly revoked.
All Tilray stockholders are encouraged to have their voices heard in regard to this very important matter concerning their investment in Tilray, regardless of the number of shares held. Tilray stockholders who have not already voted, or wish to change their vote, are strongly encouraged to do so. Tilray stockholders who held shares as of the March 12, 2021 record date are eligible to vote those shares at the April 30th Tilray Special Meeting.
If Tilray stockholders have questions or need additional information regarding the Transaction, Tilray stockholders are encouraged to contact Tilray’s shareholder communications advisor and proxy solicitation agent, Mackenzie Partners, Inc. by toll-free at 1-800-322-2885 or by e-mail at proxy@mackenziepartners.com.
About Tilray®
Tilray is a global pioneer in the research, cultivation, production, and distribution of cannabis and cannabinoids, currently serving tens of thousands of patients and consumers in 17 countries spanning five continents.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Certain information in this communication constitutes forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor created by such sections and other applicable laws. The forward-looking statements are expressly qualified by this cautionary statement. Forward-looking statements are provided for the purpose of presenting information about management’s current expectations and plans relating to the future, and readers are cautioned that such statements may not be appropriate for other purposes. Any information or statements that are contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements, including, but not limited to, statements in this communication with regards to: (i) statements relating to the strategic business combination of Aphria and Tilray and the expected timing and closing of the Transaction; the Transaction including, receipt of required shareholder approvals, court approvals and satisfaction of other closing customary conditions; (ii) estimates of pro-forma financial information of the Combined Company, including in respect of expected revenues and production of cannabis; (iii) the expected strategic and financial benefits of the business combination, including estimates of future cost reductions, synergies, including expected pre-tax synergies, savings and efficiencies; (iv) statements that the Combined Company anticipates having scalable medical and adult-use cannabis platforms expected to strengthen the leadership position in Canada, internationally and, eventually in the United States; (v) statements that the Combined Company is expected to offer a diversified and branded product offering and distribution footprint, state-of-the-art cultivation, processing and manufacturing facilities; (vi) statements in respect of operational efficiencies expected to be generated as a result of the Transaction in the amount of approximately C$100 million of pre-tax annual cost synergies; (vii) statements regarding the value and returns to shareholders expected to be generated by the business combination; (viii) expectations of future balance sheet strength and future equity; (ix) expectations regarding the Combined Company’s future M&A strategy; and (x) the expectation that the Combined Company’s shares will be listed on the Toronto Stock Exchange concurrently with, or as soon as possible after, the closing of the Transaction. Aphria and Tilray use words such as “forecast”, “future”, “should”, “could”, “enable”, “potential”, contemplate”, “believe”, “anticipate”, “estimate”, “plan”, “expect”, “intend”, “may”, “project”, “will”, “would” and the negative of these terms or similar expressions to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Certain material factors or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication, including the ability of the parties to receive, in a timely manner and on satisfactory terms, the necessary shareholder and court approvals for the Transaction, the ability of the parties to satisfy, in a timely manner, the conditions to closing of the Transaction and other expectations and assumptions concerning the Transaction. Forward-looking statements reflect current beliefs of management of Aphria and Tilray with respect to future events and are based on information currently available to each respective management team including the reasonable assumptions, estimates, analysis and opinions of management of Aphria and Tilray considering their experience, perception of trends, current conditions and expected developments as well as other factors that each respective management believes to be relevant as at the date such statements are made. Forward-looking statements involve significant known and unknown risks and uncertainties. Many factors could cause actual results, performance or achievement to be materially different from any future forward-looking statements. Factors that may cause such differences include, but are not limited to, risks assumptions and expectations described in Aphria’s and Tilray’s critical accounting policies and estimates; the adoption and impact of certain accounting pronouncements; Aphria’s and Tilray’s future financial and operating performance; the competitive and business strategies of Aphria and Tilray; the intention to grow the business, operations and potential activities of Aphria and Tilray; the ability of Aphria and Tilray to complete the Transaction; Aphria’s and Tilray’s ability to provide a return on investment; Aphria’s and Tilray’s ability to maintain a strong financial position and manage costs, the ability of Aphria and Tilray to maximize the utilization of their existing assets and investments and that the completion of the Transaction is subject to the satisfaction or waiver of a number of conditions as set forth in the Arrangement Agreement. There can be no assurance as to when these conditions will be satisfied or waived, if at all, or that other events will not intervene to delay or result in the failure to complete the Transaction. There is a risk that some or all the expected benefits of the Transaction may fail to materialize or may not occur within the time periods anticipated by Aphria and Tilray. The challenge of coordinating previously independent businesses makes evaluating the business and future financial prospects of the Combined Company following the Transaction difficult. Material risks that could cause actual results to differ from forward-looking statements also include the inherent uncertainty associated with the financial and other projections a well as market changes arising from governmental actions or market conditions in response to the COVID-19 public health crisis; the prompt and effective integration of the Combined Company; the ability to achieve the anticipated synergies and value-creation contemplated by the Transaction; the risk associated with Aphria’s and Tilray’s ability to obtain the approval of the proposed transaction by their shareholders required to consummate the Transaction and the timing of the closing of the Transaction, including the risk that the conditions to the Transaction are not satisfied on a timely basis or at all; the risk that a consent or authorization that may be required for the Transaction is not obtained or is obtained subject to conditions that are not anticipated; the outcome of any legal proceedings that may be instituted against the parties and others related to the Arrangement Agreement; unanticipated difficulties or expenditures relating to the Transaction, the response of business partners and retention as a result of the announcement and pendency of the Transaction; risks relating to the value of Tilray’s common stock to be issued in connection with the transaction; the impact of competitive responses to the announcement of the Transaction; and the diversion of management time on transaction-related issues. Readers are cautioned that the foregoing list of factors is not exhaustive. Other risks and uncertainties not presently known to Aphria and Tilray or that Aphria and Tilray presently believe are not material could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of risks and other factors, see the most recently filed annual information form of Aphria and the annual report filed on form 10-K of Tilray made with applicable securities regulatory authorities and available on SEDAR and EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and neither Aphria nor Tilray undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.
ADDITIONAL INFORMATION ABOUT THE TRANSACTION AND WHERE TO FIND IT
This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. This communication is being made in respect of the proposed transaction involving Aphria and Tilray pursuant to the terms of an arrangement agreement by and among Aphria and Tilray and may be deemed to be soliciting material relating to the proposed transaction.
In connection with the Transaction, Tilray has filed a joint proxy statement/management information circular (the “Circular”) containing important information about the Transaction and related matters. The Circular has also been made avai